Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy (Q28235697)
Jump to navigation
Jump to search
scientific article (publication date: 15 February 2009)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy |
scientific article (publication date: 15 February 2009) |
Statements
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy (English)
0 references
15 February 2009
0 references
15
0 references
4
0 references
1400-10
0 references